Bioventix (LON:BVXP) Stock Price Passes Above 50-Day Moving Average – What’s Next?

Posted by Joseph Casey on Jun 10th, 2026

Bioventix PLC (LON:BVXP – Get Free Report) shares passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of GBX 1,691.85 and traded as high as GBX 1,700. Bioventix shares last traded at GBX 1,600, with a volume of 8,422 shares traded.

Bioventix Stock Performance

The stock has a 50 day moving average price of GBX 1,691.85 and a 200 day moving average price of GBX 1,714.30. The company has a market cap of £81.51 million, a P/E ratio of 11.10 and a beta of 0.56.

Bioventix (LON:BVXP – Get Free Report) last posted its quarterly earnings data on Monday, March 30th. The biotechnology company reported GBX 69.38 EPS for the quarter. Bioventix had a return on equity of 65.83% and a net margin of 59.30%.The company had revenue of GBX 615.88 billion for the quarter. As a group, equities research analysts predict that Bioventix PLC will post 166.3066955 earnings per share for the current year.

Insider Transactions at Bioventix

In other news, insider Bruce Hiscock acquired 66 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were bought at an average price of GBX 1,679 per share, with a total value of £1,108.14. Also, insider Ian James Nicholson acquired 1,000 shares of the company’s stock in a transaction dated Friday, April 10th. The stock was purchased at an average cost of GBX 1,848 per share, for a total transaction of £18,480. In the last 90 days, insiders have bought 2,131 shares of company stock valued at $3,927,999. Corporate insiders own 6.22% of the company’s stock.

About Bioventix

(Get Free Report)

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.